According to Fortune Business Insights, the global cardiac resynchronization therapy market size was valued at USD 6.96 billion in 2025 and is projected to grow from USD 7.26 billion in 2026 to USD 9.72 billion by 2034, exhibiting a CAGR of 3.7% during the forecast period from 2026 to 2034. North America dominated the global market with a 44.25% share in 2025, supported by advanced cardiac care infrastructure and the high adoption of device-based therapies.
The growing burden of heart failure represents one of the primary factors supporting demand for cardiac resynchronization therapy. According to the source, HF Stats 2025 estimates that approximately 6.7 million Americans over the age of 20 live with heart failure, with prevalence expected to increase in the coming years.
CRT is increasingly incorporated into multidisciplinary heart failure pathways involving imaging, guideline-directed medical therapy, and electrophysiology assessment. Greater awareness of treatment eligibility and improvements in referral pathways are helping healthcare providers identify patients who may benefit from device therapy.
For detailed market insights: https://www.fortunebusinessinsights.com/cardiac-resynchronization-therapy-market-113171
One of the most important trends in the cardiac resynchronization therapy market is the growing importance of connectivity and remote follow-up. Healthcare providers are seeking systems that can reduce the burden on clinics while maintaining effective patient monitoring.
Remote monitoring and app-based connectivity can streamline alerts, reduce routine visits, and help healthcare professionals identify potential patient deterioration earlier. This is particularly relevant as heart failure patient volumes increase and electrophysiology workforces remain constrained.
The market is also witnessing growing interest in approaches designed to support more physiologic activation. Conduction-system pacing concepts and devices compatible with newer implantation techniques may increase treatment feasibility for patients who present complex clinical or anatomical challenges.
Guidelines also continue to influence the market by promoting systematic patient selection and follow-up and by positioning device therapy alongside modern pharmacological treatment.
The increasing prevalence of heart failure is a major driver of the cardiac resynchronization therapy market. As the number of patients requiring advanced heart failure management increases, demand for device-based treatment is expected to rise.
Clearer, guideline-based decision-making is encouraging eligible patients to undergo evaluation for CRT instead of remaining under prolonged observation. Multidisciplinary heart failure programs increasingly coordinate imaging, medical therapy optimization, and electrophysiology assessments, helping reduce the possibility of eligible patients being overlooked.
Professional guidelines, including European heart failure recommendations, continue to provide structured approaches to diagnosis, pharmacotherapy, and device therapy. This standardization is supporting the adoption of CRT across healthcare settings.
However, high procedural complexity, specialized equipment requirements, variable patient response, and the total cost of therapy can restrain market growth. CRT implantation requires specialized operators, careful lead placement, post-implant optimization, and continued programming and follow-up.